GlaxoSmithKline Operating Income from 2010 to 2024

GSK Stock

USD 40.59 0.84 2.11%

GlaxoSmithKline PLC Operating Income yearly trend continues to be quite stable with very little volatility. The value of Operating Income is projected to decrease to about 5 B. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit GlaxoSmithKline PLC ADR generates from its operations. View All Fundamentals

Operating Income

First Reported

1985-09-30

Previous Quarter

1.9 B

Current Value

1.1 B

Quarterly Volatility

1.5 B

Black Monday

Oil Shock

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check GlaxoSmithKline PLC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GlaxoSmithKline main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 B, Interest Expense of 502.2 M or Total Revenue of 19.9 B, as well as many exotic indicators such as Price To Sales Ratio of 3.33, Dividend Yield of 0.0181 or PTB Ratio of 9.29. GlaxoSmithKline financial statements analysis is a perfect complement when working with GlaxoSmithKline PLC Valuation or Volatility modules.

This module can also supplement GlaxoSmithKline PLC's financial leverage analysis and stock options assessment as well as various GlaxoSmithKline PLC Technical models . Check out the analysis of GlaxoSmithKline PLC Correlation against competitors.

Latest GlaxoSmithKline PLC's Operating Income Growth Pattern

Below is the plot of the Operating Income of GlaxoSmithKline PLC ADR over the last few years. Operating Income is the amount of profit realized from GlaxoSmithKline PLC ADR operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of GlaxoSmithKline PLC ADR is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. GlaxoSmithKline PLC's Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in GlaxoSmithKline PLC's overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Pretty Stable

Compare to Others All Fundamentals

Operating Income

Timeline

GlaxoSmithKline Operating Income Regression Statistics

	Arithmetic Mean	5,889,045,527
	Geometric Mean	5,101,607,473
	Coefficient Of Variation	40.90
	Mean Deviation	1,855,812,034
	Median	6,433,000,000
	Standard Deviation	2,408,896,258
	Sample Variance	5802781.2T
	Range	9.7B
	R-Value	0.18
	Mean Square Error	6054431.3T
	R-Squared	0.03
	Significance	0.53
	Slope	95,081,358
	Total Sum of Squares	81238936.6T

GlaxoSmithKline Operating Income History

	2024	5 B
	2023	7 B
	2022	6.4 B
	2021	6.2 B
	2020	7.8 B
	2019	7 B
	2018	5.5 B

Other Fundumenentals of GlaxoSmithKline PLC ADR

Non Operating Income Net Other

GlaxoSmithKline PLC Operating Income component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Accounts Payable	Short Term Investments	Total Liab	Total Current Assets	Capital Stock	Short Term Debt	Common Stock	Retained Earnings	Intangible Assets	Long Term Debt	Good Will	Property Plant Equipment	Current Deferred Revenue	Net Receivables	Treasury Stock	Net Tangible Assets	Long Term Investments	Short Long Term Debt	Long Term Debt Total	Capital Surpluse	Net Invested Capital	Net Working Capital	Cash And Equivalents
Total Assets		0.5	0.9	0.77	-0.07	0.97	0.91	0.7	0.71	0.7	0.12	0.94	0.5	0.95	-0.16	0.23	0.56	0.19	-0.26	0.57	-0.59	0.59	0.4	0.49	0.5	0.2
Total Stockholder Equity	0.5		0.43	0.1	0.39	0.31	0.48	0.33	0.25	0.33	0.88	0.51	0.38	0.68	-0.23	0.1	0.69	0.13	0.06	0.75	-0.27	0.78	0.7	0.42	0.82	-0.44
Net Debt	0.9	0.43		0.7	-0.09	0.89	0.82	0.65	0.9	0.65	0.08	0.82	0.64	0.84	0.02	0.2	0.5	0.11	-0.05	0.47	-0.49	0.65	0.32	0.58	0.5	0.24
Accounts Payable	0.77	0.1	0.7		-0.1	0.82	0.67	0.53	0.59	0.53	-0.23	0.74	0.35	0.69	-0.06	0.31	0.39	0.09	-0.15	0.39	-0.51	0.27	0.08	0.13	0.24	0.37
Short Term Investments	-0.07	0.39	-0.09	-0.1		-0.09	0.13	0.0	-0.09	0.0	0.42	-0.18	-0.24	0.03	-0.51	0.18	0.39	0.27	0.21	0.54	-0.27	0.11	0.67	-0.19	0.61	-0.51
Total Liab	0.97	0.31	0.89	0.82	-0.09		0.91	0.74	0.75	0.74	-0.11	0.88	0.47	0.86	-0.15	0.23	0.45	0.2	-0.27	0.48	-0.63	0.46	0.33	0.42	0.4	0.25
Total Current Assets	0.91	0.48	0.82	0.67	0.13	0.91		0.88	0.65	0.88	0.06	0.72	0.6	0.79	-0.04	-0.04	0.4	0.15	-0.2	0.48	-0.54	0.41	0.41	0.31	0.47	0.13
Capital Stock	0.7	0.33	0.65	0.53	0.0	0.74	0.88		0.55	1.0	-0.14	0.49	0.74	0.55	0.23	-0.33	0.1	0.03	-0.16	0.25	-0.4	0.18	0.21	0.14	0.21	-0.02
Short Term Debt	0.71	0.25	0.9	0.59	-0.09	0.75	0.65	0.55		0.55	-0.03	0.65	0.56	0.66	0.12	0.25	0.42	-0.1	0.14	0.34	-0.31	0.55	0.19	0.53	0.37	0.21
Common Stock	0.7	0.33	0.65	0.53	0.0	0.74	0.88	1.0	0.55		-0.14	0.49	0.74	0.55	0.23	-0.33	0.1	0.03	-0.16	0.25	-0.4	0.18	0.21	0.14	0.21	-0.02
Retained Earnings	0.12	0.88	0.08	-0.23	0.42	-0.11	0.06	-0.14	-0.03	-0.14		0.2	0.03	0.37	-0.29	0.18	0.63	0.03	0.2	0.6	0.02	0.66	0.6	0.32	0.7	-0.44
Intangible Assets	0.94	0.51	0.82	0.74	-0.18	0.88	0.72	0.49	0.65	0.49	0.2		0.38	0.96	-0.26	0.4	0.61	0.22	-0.31	0.61	-0.57	0.7	0.35	0.57	0.51	0.14
Long Term Debt	0.5	0.38	0.64	0.35	-0.24	0.47	0.6	0.74	0.56	0.74	0.03	0.38		0.44	0.65	-0.46	0.02	-0.19	0.1	0.03	-0.06	0.29	-0.08	0.25	0.12	0.13
Good Will	0.95	0.68	0.84	0.69	0.03	0.86	0.79	0.55	0.66	0.55	0.37	0.96	0.44		-0.26	0.36	0.73	0.21	-0.17	0.73	-0.58	0.76	0.52	0.56	0.67	0.03
Property Plant Equipment	-0.16	-0.23	0.02	-0.06	-0.51	-0.15	-0.04	0.23	0.12	0.23	-0.29	-0.26	0.65	-0.26		-0.65	-0.46	-0.59	0.35	-0.64	0.54	-0.34	-0.65	-0.17	-0.56	0.39
Current Deferred Revenue	0.23	0.1	0.2	0.31	0.18	0.23	-0.04	-0.33	0.25	-0.33	0.18	0.4	-0.46	0.36	-0.65		0.7	0.16	0.21	0.57	-0.42	0.46	0.45	0.35	0.49	-0.12
Net Receivables	0.56	0.69	0.5	0.39	0.39	0.45	0.4	0.1	0.42	0.1	0.63	0.61	0.02	0.73	-0.46	0.7		0.02	0.33	0.85	-0.41	0.72	0.77	0.4	0.81	-0.23
Treasury Stock	0.19	0.13	0.11	0.09	0.27	0.2	0.15	0.03	-0.1	0.03	0.03	0.22	-0.19	0.21	-0.59	0.16	0.02		-0.5	0.37	-0.78	0.22	0.34	0.1	0.33	-0.23
Net Tangible Assets	-0.26	0.06	-0.05	-0.15	0.21	-0.27	-0.2	-0.16	0.14	-0.16	0.2	-0.31	0.1	-0.17	0.35	0.21	0.33	-0.5		0.04	0.24	0.01	0.15	-0.04	0.12	-0.13
Long Term Investments	0.57	0.75	0.47	0.39	0.54	0.48	0.48	0.25	0.34	0.25	0.6	0.61	0.03	0.73	-0.64	0.57	0.85	0.37	0.04		-0.65	0.76	0.88	0.45	0.92	-0.52
Short Long Term Debt	-0.59	-0.27	-0.49	-0.51	-0.27	-0.63	-0.54	-0.4	-0.31	-0.4	0.02	-0.57	-0.06	-0.58	0.54	-0.42	-0.41	-0.78	0.24	-0.65		-0.4	-0.56	-0.25	-0.53	0.24
Long Term Debt Total	0.59	0.78	0.65	0.27	0.11	0.46	0.41	0.18	0.55	0.18	0.66	0.7	0.29	0.76	-0.34	0.46	0.72	0.22	0.01	0.76	-0.4		0.6	0.81	0.83	-0.29
Capital Surpluse	0.4	0.7	0.32	0.08	0.67	0.33	0.41	0.21	0.19	0.21	0.6	0.35	-0.08	0.52	-0.65	0.45	0.77	0.34	0.15	0.88	-0.56	0.6		0.36	0.87	-0.59
Net Invested Capital	0.49	0.42	0.58	0.13	-0.19	0.42	0.31	0.14	0.53	0.14	0.32	0.57	0.25	0.56	-0.17	0.35	0.4	0.1	-0.04	0.45	-0.25	0.81	0.36		0.52	-0.1
Net Working Capital	0.5	0.82	0.5	0.24	0.61	0.4	0.47	0.21	0.37	0.21	0.7	0.51	0.12	0.67	-0.56	0.49	0.81	0.33	0.12	0.92	-0.53	0.83	0.87	0.52		-0.47
Cash And Equivalents	0.2	-0.44	0.24	0.37	-0.51	0.25	0.13	-0.02	0.21	-0.02	-0.44	0.14	0.13	0.03	0.39	-0.12	-0.23	-0.23	-0.13	-0.52	0.24	-0.29	-0.59	-0.1	-0.47

Click cells to compare fundamentals

About GlaxoSmithKline PLC Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include GlaxoSmithKline PLC income statement, its balance sheet, and the statement of cash flows. GlaxoSmithKline PLC investors use historical funamental indicators, such as GlaxoSmithKline PLC's Operating Income, to determine how well the company is positioned to perform in the future. Although GlaxoSmithKline PLC investors may use each financial statement separately, they are all related. The changes in GlaxoSmithKline PLC's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on GlaxoSmithKline PLC's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on GlaxoSmithKline PLC Financial Statements. Understanding these patterns can help to make the right decision on long term investment in GlaxoSmithKline PLC. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Operating Income	7 B	5 B
Non Operating Income Net Other	0.00	0.00

GlaxoSmithKline PLC Investors Sentiment

The influence of GlaxoSmithKline PLC's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in GlaxoSmithKline. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.

Investor biases related to GlaxoSmithKline PLC's public news can be used to forecast risks associated with an investment in GlaxoSmithKline. The trend in average sentiment can be used to explain how an investor holding GlaxoSmithKline can time the market purely based on public headlines and social activities around GlaxoSmithKline PLC ADR. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.

GlaxoSmithKline PLC's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for GlaxoSmithKline PLC's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average GlaxoSmithKline PLC's news discussions. The higher the estimated score, the more favorable is the investor's outlook on GlaxoSmithKline PLC.

GlaxoSmithKline PLC Implied Volatility

25.2

GlaxoSmithKline PLC's implied volatility exposes the market's sentiment of GlaxoSmithKline PLC ADR stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if GlaxoSmithKline PLC's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that GlaxoSmithKline PLC stock will not fluctuate a lot when GlaxoSmithKline PLC's options are near their expiration.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards GlaxoSmithKline PLC in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, GlaxoSmithKline PLC's short interest history, or implied volatility extrapolated from GlaxoSmithKline PLC options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether GlaxoSmithKline PLC ADR is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlaxoSmithKline Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glaxosmithkline Plc Adr Stock. Highlighted below are key reports to facilitate an investment decision about Glaxosmithkline Plc Adr Stock:

How To Invest In GlaxoSmithKline

Details

Is GlaxoSmithKline Stock a good investment?

Details

What is GlaxoSmithKline PLC's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of GlaxoSmithKline PLC Correlation against competitors.

You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

Complementary Tools for GlaxoSmithKline Stock analysis

When running GlaxoSmithKline PLC's price analysis, check to measure GlaxoSmithKline PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline PLC is operating at the current time. Most of GlaxoSmithKline PLC's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlaxoSmithKline PLC's price. Additionally, you may evaluate how the addition of GlaxoSmithKline PLC to your portfolios can decrease your overall portfolio volatility.

	Transaction History View history of all your transactions and understand their impact on performance
	Content Syndication Quickly integrate customizable finance content to your own investment portal
	Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
	Commodity Directory Find actively traded commodities issued by global exchanges
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios

Is GlaxoSmithKline PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.77)

Dividend Share

0.58

Earnings Share

2.99

Revenue Per Share

14.97

Quarterly Revenue Growth

0.092

The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

GlaxoSmithKline Operating Income from 2010 to 2024

Latest GlaxoSmithKline PLC's Operating Income Growth Pattern

GlaxoSmithKline Operating Income Regression Statistics

GlaxoSmithKline Operating Income History

Other Fundumenentals of GlaxoSmithKline PLC ADR

GlaxoSmithKline PLC Operating Income component correlations

About GlaxoSmithKline PLC Financial Statements

GlaxoSmithKline PLC Investors Sentiment

GlaxoSmithKline PLC Implied Volatility

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for GlaxoSmithKline Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY